Cohort  (NSCLC cohort) \r\n* In regards to administration of prior anti-PD- or anti PD-L antibodies, a patients:\r\n** Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy\r\n** All adverse events (AEs) while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study\r\n** Must not have experienced a >= grade  immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy; NOTE: subjects with endocrine AE of =< grade  are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic\r\n** Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of >  mg prednisone or equivalent per day\r\n* Eligibility for Food and Drug Administration (FDA)-approved agents targeting the EGFR, ROS or ALK pathway, which should be evaluated as per standard of care; exceptions to this requirement may be considered on a case-by-case basis by the principal investigator if the patient was previously treated with another targeted agent
Patients who had prior grade  or higher immune-related adverse event (e.g. pneumonitis, hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer vaccine, cytokine, etc.) are not eligible
Any prior >= grade  immune-related adverse event while receiving immunotherapy; patients will be excluded if experiencing any unresolved grade  immune related adverse events at the time of study entry; participants with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product
Treatment-related, immune-mediated adverse events associated with prior immunotherapeutic agents
Adverse events from prior anti-cancer therapy that have not resolved to Grade ? . Clinically stable patients with manageable immune-related adverse events resulting from prior cancer immunotherapy may be eligible for the study.
Must not have experienced any ? Grade  AE nor any neurologic or ocular AE of any grade while receiving prior checkpoint inhibitors.
History of severe adverse events, in the investigator's opinion, related to ramucirumab.
Participant must not have a prior grade greater than or equal to  immune-mediated neurotoxicity or pneumonitis while receiving immunotherapy.
Prior grade greater than or equal to  immune-mediated neurotoxicity or pneumonitis (or any other unresolved or symptomatic adverse event in the last  months) while receiving immunotherapy.
History of CTCAE >= grade  immune mediated endocrinopathy from prior cancer immunotherapy
Participants must have recovered to grade =<  or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include but are not limited to alopecia, laboratory values listed per inclusion criteria and lymphopenia)
All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values) must be =< grade  according to the Common Terminology Criteria for Adverse Events version  (CTCAE version .) at the time of randomization, subjects with endocrinopathies (e.g. hypopituitarism, hypothyroidism, hypoadrenalism) caused by immune therapies currently on adequate hormone replacement WILL be permitted, subjects with endocrinopathies (e.g. hypopituitarism, hypothyroidism, hypoadrenalism) caused by immune therapies currently on adequate hormone replacement WILL be permitted
A life-threatening (Grade ) immune-mediated adverse event related to prior immunotherapy.
Participants must not have experienced a grade >=  immune-related adverse event (AE) or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy, or experienced a toxicity of any grade that led to permanent discontinuation of prior immunotherapy as a result of the toxicity. Participants with prior endocrine adverse events of grade =<  are permitted to enroll if stably maintained on appropriate replacement therapy and are asymptomatic. In the setting of prior immune-related AE, participants must not have required the use of additional immunosuppressive agents other than corticosteroids for the management of the adverse event(s), not have experienced recurrence of the adverse event if re-challenged, and not currently requiring maintenance doses of >  mg of prednisone or equivalent per day at the time of enrollment.
Any adverse events related to previous therapies for breast cancer that have not resolved to ?Grade .
Must not have experienced a Grade ? immune-related AE or an immune-related neurologic or ocular AE, pneumonitis or cardiomyopathy of any grade while receiving prior immunotherapy.
History of grade  immune-related adverse events requiring treatment with prednisone, or grade  immune-related adverse events requiring prednisone >  mg/kg for >  weeks, if previously treated with ipilimumab
Patients with prior ? Grade , serious, or life threatening immune-mediated reactions following prior anti-PD- or other immune-oncology therapies
Have experienced a Grade ? AE or a neurologic or ocular AE of any grade while receiving prior immunotherapy.
History of severe immune-related adverse effects from CEA-ILv or anti-PD- (nivolumab, pembrolizumab) or anti-PD-L (atezolizumab) therapies (Common Terminology Criteria for Adverse Events Grade  and )
Any prior grade >=  immune related adverse events immune-mediated adverse events (imAE) while receiving immunotherapy, including anti-cytotoxic T-lymphocyte protein  (CTLA) treatment, or any unresolved imAE > grade ; Note: active or history of vitiligo will not be a basis for exclusion
Patient with any active immune toxicity of Grade  or greater or any other severe or Grade  treatment-related adverse event.
Cohort A and C only: Intolerance or serious adverse immune related adverse events (irAEs) that were symptomatic or required or continues to require ongoing immunosuppression to previous immune checkpoint therapy.
History of any of the following toxicities associated with a prior immunotherapy: \r\n* Grade >  immune mediated adverse event that was considered related to previous immunotherapy and required immune suppressive therapy\r\n* Immune mediated adverse event that was considered related to previous immunotherapy and is still > grade  with immune suppressive therapy
In immunotherapy pretreated patients, any history of dose-limiting toxicity with prior immunotherapy agents, including grade / immune-related adverse events (irAEs); irreversible irAEs; grade >=  irAEs that did not respond to steroid rescue; or neurologic irAE with significant clinical sequelae
Grade  or  non-hematological, treatment-related adverse event (AE)s
Prior treatment with immune checkpoint inhibitors is allowed, provided that no treatment-related grade >=  adverse events (other than grade  endocrinopathy managed with replacement therapy) were observed and at least a minimum of  days have elapsed between the last dose of prior treatment and the proposed cycle  day 
Patients with history of any Grade  or Grade  adverse events from prior ipilimumab therapy, if administered in the past.
History of grade  or higher immune-mediated adverse event (including AST/ALT elevations that where considered drug related and cytokine release syndrome) that was considered related to prior immune-modulatory therapy (e.g., checkpoint inhibitors, costimulatory agents etc.) or any grade immune-related adverse events (AEs) that required immune suppressive therapy
Patients who have previously received a-PD- and/or anti-CTLA- will be eligible, unless they have ongoing > grade  adverse event (AE) side effects of such therapy. Ongoing physiologic replacement doses for adrenal and thyroid insufficiency are allowed on protocol
Ongoing or recent (within  years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events
Prior treatment with other immune-modulating agents within fewer than  weeks prior to the first dose of REGN, or associated with immune-mediated adverse events that were ? grade  within  days prior to the first dose of REGN, or associated with toxicity that resulted in discontinuation of the immune-modulating agent. Examples of immune-modulating agents include therapeutic vaccines, cytokine treatments, or agents that target cytotoxic T-lymphocyte antigen  (CTLA-), -BB (CD), or OX-.
History of grade  immune-related adverse events requiring treatment with prednisone or history of grade  immune-related adverse events requiring prednisone >  mg/kg for >  weeks
Has experienced immune-related adverse events (AEs) (irAEs) while receiving prior immunotherapy (including anti-CTLA treatment) and assessed as CTCAE grade >= 
Patients that had grade / immune-related adverse events (AEs) on ipilimumab that required more than  weeks of immune suppression with corticosteroids
Must not have experienced a Grade ? immune-related AE or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy.
Have a history of intolerance, hypersensitivity, or treatment discontinuation due to severe immune adverse events on prior immunotherapy, or documented presence of neutralizing anti-drug antibody to nivolumab, ipilimumab, or pembrolizumab. Subjects who discontinued prior immunotherapies for immune-related adverse events that are well-controlled with appropriate treatment may be enrolled if approved by the Medical Monitor.
Unresolved immune-related adverse events following prior biological therapy
History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within  days of randomization* or a prior history of severe (grade  or ) immune mediated toxicity from other immune therapy.
Full resolution of ipilimumab related adverse events (AEs) to baseline (including immune related adverse events [irAEs]) off of steroid treatment (>  mg/day prednisone or equivalent dose) for irAEs for at least two weeks prior to first dose of study drug\r\n* No history of severe irAEs from ipilimumab of Common Terminology Criteria for Adverse Events (CTCAE) grade  requiring steroid treatment; no history of CTCAE grade  requiring steroid treatment (>  mg/day prednisone or equivalent dose) for >  weeks\r\n* Minimum of four weeks (wash out period) from the last dose of ipilimumab
All irAEs while receiving prior immunotherapy must have resolved to ? grade  or Baseline prior to Screening for this study. Must not have experienced a ? grade  immune-related AE within the past  weeks or any grade  life- threatening irAE (regardless of duration) or neurologic or ocular AE of any grade while receiving prior immunotherapy (NOTE: Subjects with endocrine AE of any grade are permitted to enroll if they are stably maintained on appropriate replacement therapy, but must have no history of adrenal crisis and be asymptomatic)
Experiencing CTCAE grade > events, experienced immune-related grade ?AEs with prior immunotherapy
History of immune-related adverse event from prior immunotherapy treatment that has not improved to grade -; subjects with grade  hypothyroidism and grade  adrenal insufficiency requiring continued medical treatment may enroll provided that they are asymptomatic and stable on their dose of hormone replacement
Hospitalization within  days of enrollment for cancer related events
Unresolved immune-related adverse events following prior biological therapy. Subjects with asymptomatic endocrinopathy may enroll.
Past discontinuation of bortezomib due to associated grade  or higher adverse event
Any grade - adverse event related to HSV-Tk infusion or a grade  adverse event that does not resolve to no more than grade  before the next infusion
Prior Grade  or higher immune-related AEs or any ocular toxicity on prior immunotherapy as per protocol-defined criteria.
Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-related treatment-emergent adverse events (irTEAEs)
Adverse events resulting from previous therapies have not recovered to grade  or less
Patients with any of the following adverse events at the time of enrollment are not eligible:\r\n*Grade ?  hyponatremia (serum Na ?  mmol/L)
If received prior immunotherapy must not have experienced one of the following:\r\n* A toxicity that led to permanent discontinuation of prior immunotherapy\r\n* All adverse events (AEs) while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study\r\n* Must not have experienced a >= grade  immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy; NOTE: Patients with endocrine AE of =< grade  are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic\r\n* Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE and must not have experienced recurrence of an AE if re-challenged
Any prior grade >/=  immune-related adverse event (imAE) while receiving any previous immunotherapy agent, or any unresolved imAE > grade 
The corticosteroids prednisone and dexamethasone may be continued until the day before treatment start if all related adverse events are controlled at CTCAE version . grade =< 
Grade - adverse event (AE) associated with prior anti-VEGF therapy; grade  hypertension that was readily managed will be permitted
Subjects previously treated with anti-program death- (PD) or anti-cytotoxic T-lymphocyte associated antigen  (CTLA-) antibodies must not have discontinued therapy due to any treatment-related adverse events including immune-related adverse events. Prior treatment-related adverse events should also be fully resolved and not requiring treatment for at least  days prior to randomization.
A history of any grade immune-related ocular event.
A history of Grade ? immune-related adverse event regardless of offending agent.
Previously received an immune therapy that was discontinued due to immune-related AEs, regardless of grade.
Clinically significant persistent immune-related adverse events following prior therapy.
Patients who have not recovered from serious adverse events (as determined by treating doctor of medicine [MD]) related to surgery
Must not have experienced a ? Grade  AE or neurologic or ocular AE of any grade while receiving prior immunotherapy
Patients with any malignancy who will receive HDMTX given as a  g/m^ infusion over  hours and a history of >=  of the following:\r\n* Documented decreased renal function, as defined as creatinine greater than . x baseline or glomerular filtration rate (GFR) <  ml/min/.m^\r\n* History of prior nephrotoxicity with HDMTX as evidence by increased creatinine to . x baseline or need for dialysis or carboxypeptidase\r\n* History of grade  adverse event (AE) related to HDMTX (mucositis, myelosuppression, nephrotoxicity, hepatotoxicity) based on the National Institutes of Health (NIH) Common Terminology Criteria for Adverse Events (CTCAE) version .\r\n* Provider concern patient is at risk for MTX toxicity, such as a prior history of treatment with nephrotoxic chemotherapy, history of HDMTX-related neurotoxicity, or antimicrobial/antifungal therapy
All adverse events (excluding alopecia, acne, rash) due to agents administered more than  weeks earlier should recover to =< grade ; patients with hematologic malignancies are expected to have hematologic abnormalities at study entry; these abnormalities which are thought to be primarily related to the underlying leukemia, are not considered to be toxicities (adverse events [AE]) and do not need to resolve to =< grade 
History of immune-mediated adverse events requiring immunosuppressive therapy or were grade  or higher related to prior immune-modulatory therapy
Patients are excluded from re-induction if they have experienced any related dose-limiting toxicities, delayed dosing beyond  days due to tremelimumab-related adverse events (AEs), or have been taken off treatment due to toxicity
Resolution of prior therapy acute adverse events.
Patient did not discontinue due to a Grade ? related adverse event
Had a prior anti-cancer monoclonal antibody (except immune CPI in the case of melanoma subjects) within  days prior to start of study treatment, or failure to recover to CTCAE Grade  or better from the adverse events of prior therapies
History of Grade ? infusion-related adverse events (AEs) or hypersensitivity to NEOD
History of Grade ? infusion-associated adverse events (AEs) or hypersensitivities to NEOD or any of its excipients
Unresolved immune related adverse events following prior biological therapy.
Has ongoing acute clinical adverse events NCI CTCAE Grade > resulting from prior cancer therapies (except alopecia, TKI-related hand-foot syndrome, or thyroid dysfunction).
Subjects who are able and agree to report adverse events (AEs) during the required reporting period.
Grade  (or higher) adverse event assessed as treatment-related at any time during the course of treatment under Protocol -.
Failure to recover to grade  or less all prior adverse events.
Grade  immune mediated adverse event that was considered related to previous immunotherapy and required immune suppressive therapy;
Grade  hepatic function related adverse event that persisted more than  week, was considered related to immunotherapy, or required treatment discontinuation or immunosuppressive therapy
Any prior Grade ?  immune-related adverse event while receiving immunotherapy
Participants with worsening adverse events
Patients must have reached Week  of the core protocol in immune-related complete response (irCR), immune-related partial response (irPR), immune-related stable disease (irSD), or immune-related progressive disease (irPD) (unconfirmed) with evidence of tumor inflammatory reaction.
Any history of an immune-related Grade  adverse event attributed to prior CIT (other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase)
Any history of an immune-related Grade  adverse event attributed to prior CIT (other than hypothyroidism managed with replacement therapy) that resulted in permanent discontinuation of the prior immunotherapeutic agent and/or occurred less than or equal to (<=)  months prior to Cycle  Day 
All immune-related adverse events related to prior CIT (other than endocrinopathy managed with replacement therapy or stable vitiligo) must have resolved completely to baseline
Prior treatment with systemic immune modulating agents (other than anti-PD-/PD-L agents) that was within  days prior to enrollment, or within  days prior to enrollment if there was an immune related adverse event, or associated with toxicity that resulted in discontinuation of the immune modulating agent
Patient has not recovered to baseline or less than Grade  from non-hematologic adverse events related to any anticancer therapy received prior to signing informed consent on the Treatment Extension study, with the exception of hair loss.
Patient who had not recovered to grade  or better from any adverse events (except alopecia, nausea, vomiting) related to previous antineoplastic therapy before screening procedures are initiated, as allowed in inclusion criteria
No significant immune-related adverse event due to the nivolumab plus ipilimumab dose received in the neoadjuvant setting, as follows:\r\n* Any grade myocarditis, including an asymptomatic troponin elevation felt to be related to nivolumab plus ipilimumab\r\n* Any grade neurologic complication (e.g. meningitis, encephalitis, neuropathy); study chair should be contacted if there is any question whether an adverse event (AE) was neurologic in nature\r\n* Grade  or higher pneumonitis\r\n* Grade  colitis\r\n* Grade  or higher anemia (due to drug; unrelated anemia is not exclusionary)\r\n* Thyroid/adrenal AEs regardless of grade that have stabilized or are clinically asymptomatic are eligible\r\n* Fatigue, regardless of grade, is not a contraindication to randomization\r\n* Grade  AST or ALT elevation\r\n* Asymptomatic elevated amylase and lipase, regardless of grade, are not contraindications to randomization\r\n* Grade  rash; grade  rash is not a contraindication to randomization; any oropharyngeal lesions or bullous skin lesions that are suggestive of toxic epidermal necrolysis or Stevens-Johnson syndrome are contraindications to randomization regardless of the grade of rash\r\n** If not specified above, other Common Terminology Criteria for Adverse Events (CTCAE) grade  or higher AEs deemed possibly related to the nivolumab plus ipilimumab are exclusions to randomization; AEs that were attributable to surgery or adjuvant RT would not be contraindications to randomization
Patients intolerant to prior immunotherapy (unable to continue/receive due to immune-related AE).
Available for follow-up of their disease after treatment until progressive disease is documented and resolution of related adverse events until < grade 
Any grade immune-related pneumonitis, cardiomyopathy, or hepatitis
Patients on adjuvant ipilimumab are allowed to participate at least  days from drug discontinuation as long as they have at most grade  adverse events (or grade  if they have to received hormone replacement therapy for their otherwise grade  ipilimumab-induced autoimmune endocrinopathies)
Any prior adverse events associated with prior MRI that are not related to injection of contrast agents or other medicines
Completed a prior therapy less than (<)  weeks prior to first dose and for whom adverse events (AEs) related to prior therapy had not returned to baseline or improved to Grade .
